Neuronetics (NASDAQ:STIM) Announces Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Neuronetics (NASDAQ:STIM) issued its quarterly earnings data on Tuesday. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.07), Zacks reports. Neuronetics had a negative net margin of 50.09% and a negative return on equity of 141.24%. Neuronetics updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Neuronetics Price Performance

Shares of NASDAQ:STIM opened at $4.26 on Tuesday. The company has a 50 day moving average of $2.85 and a 200 day moving average of $1.62. The stock has a market cap of $129.28 million, a P/E ratio of -3.46 and a beta of 2.17. Neuronetics has a 12 month low of $0.52 and a 12 month high of $5.07. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90.

Insider Activity at Neuronetics

In other Neuronetics news, CFO Stephen Furlong sold 14,836 shares of Neuronetics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.28, for a total transaction of $48,662.08. Following the completion of the sale, the chief financial officer now directly owns 482,572 shares in the company, valued at $1,582,836.16. The trade was a 2.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Keith J. Sullivan sold 40,992 shares of Neuronetics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.28, for a total transaction of $134,453.76. Following the sale, the chief executive officer now owns 1,283,362 shares of the company’s stock, valued at approximately $4,209,427.36. The trade was a 3.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 98,125 shares of company stock valued at $348,876. Corporate insiders own 9.80% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.